

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Riociguat

February 10, 2026

Therapeutic category

Other cardiovascular agents

Non-proprietary name

Riociguat

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision											
<p>10. INTERACTIONS</p> <p>10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)</p> <p>(N/A)</p>	<p>10. INTERACTIONS</p> <p>10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)</p> <table border="1" data-bbox="1133 536 1995 1254"> <thead> <tr> <th data-bbox="1133 536 1384 635">Drugs</th> <th data-bbox="1388 536 1771 635">Signs, symptoms, and treatment</th> <th data-bbox="1776 536 1995 635">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="1133 635 1384 734"><u>Ensitrelvir fumaric acid</u></td> <td data-bbox="1388 635 1771 734">The blood concentration of <u>riociguat</u> may increase.</td> <td data-bbox="1776 635 1995 734">The clearance of <u>riociguat</u> is</td> </tr> <tr> <td data-bbox="1133 734 1384 1254"><u>Lonafarnib</u></td> <td data-bbox="1388 734 1771 1254"> <p>If administration of <u>riociguat</u> is started in patients being treated with these drugs, starting at a dose of 0.5 mg 3 times daily should also be considered.</p> <p>If administration of these drugs is started while receiving <u>riociguat</u>, dose reduction of <u>riociguat</u> should be considered.</p> </td> <td data-bbox="1776 734 1995 1254"> <p>decreased by the inhibition of CYP3A by these drugs.</p> </td> </tr> </tbody> </table>			Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<u>Ensitrelvir fumaric acid</u>	The blood concentration of <u>riociguat</u> may increase.	The clearance of <u>riociguat</u> is	<u>Lonafarnib</u>	<p>If administration of <u>riociguat</u> is started in patients being treated with these drugs, starting at a dose of 0.5 mg 3 times daily should also be considered.</p> <p>If administration of these drugs is started while receiving <u>riociguat</u>, dose reduction of <u>riociguat</u> should be considered.</p>	<p>decreased by the inhibition of CYP3A by these drugs.</p>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors										
<u>Ensitrelvir fumaric acid</u>	The blood concentration of <u>riociguat</u> may increase.	The clearance of <u>riociguat</u> is										
<u>Lonafarnib</u>	<p>If administration of <u>riociguat</u> is started in patients being treated with these drugs, starting at a dose of 0.5 mg 3 times daily should also be considered.</p> <p>If administration of these drugs is started while receiving <u>riociguat</u>, dose reduction of <u>riociguat</u> should be considered.</p>	<p>decreased by the inhibition of CYP3A by these drugs.</p>										

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.